Skip to main content
Premium Trial:

Request an Annual Quote

Serenex Broadens Proteomic Profiling Services for GSK

NEW YORK, Jan. 11 (GenomeWeb News) - Serenex has broadened its deal with GlaxoSmithKline, providing the drug maker with compound-profiling services using its purine proteomics technology, the Durham, NC-based company said today.

 

GSK scientists at any location can now submit compounds to Serenex, which will profile them against specific tissues and cell lines using its Proteome Mining Technology. The technology allows scientists to study the specificity of compounds for purine-binding proteins.

 

Serenex signed its first deal with GSK in 2003. The new agreement "will enable Serenex to more fully apply its technology to a larger number of GSK programs," said Serenex CEO Richard Kent in a statement.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.